CY1111372T1 - Ανοσολογικη συνθεση και εμβολια που περιεχουν ν-φορμυλομεθειονυλο πεπτιδιο ως ανοσοενισχυτικο - Google Patents

Ανοσολογικη συνθεση και εμβολια που περιεχουν ν-φορμυλομεθειονυλο πεπτιδιο ως ανοσοενισχυτικο

Info

Publication number
CY1111372T1
CY1111372T1 CY20111100355T CY111100355T CY1111372T1 CY 1111372 T1 CY1111372 T1 CY 1111372T1 CY 20111100355 T CY20111100355 T CY 20111100355T CY 111100355 T CY111100355 T CY 111100355T CY 1111372 T1 CY1111372 T1 CY 1111372T1
Authority
CY
Cyprus
Prior art keywords
formylmethylene
administrative
pipe
vaccines containing
immunological composition
Prior art date
Application number
CY20111100355T
Other languages
English (en)
Inventor
Jeannine Alexander
William I Cox
Original Assignee
Connaught Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Technology Corporation filed Critical Connaught Technology Corporation
Publication of CY1111372T1 publication Critical patent/CY1111372T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/917—Vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ανοσολογικά ανοσοενισχυτικά που αποτελούνται από το Ν-φορμυλο μεθειονυλο πεπτίδιο fMLP. To fMLP, όταν χρησιμοποιείται ως ένα ανοσοενισχυτικό σε συμφωνία με την παρούσα εφεύρεση, φροντίζει για μία ανοσοαπόκριση σε υπο-βέλτιστες δόσεις των ανασυνδυασμένων αντιγόνων.
CY20111100355T 1998-12-18 2011-04-05 Ανοσολογικη συνθεση και εμβολια που περιεχουν ν-φορμυλομεθειονυλο πεπτιδιο ως ανοσοενισχυτικο CY1111372T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/216,702 US6017537A (en) 1998-12-18 1998-12-18 Formyl methionyl peptide vaccine adjuvant
EP07007842A EP1800692B1 (en) 1998-12-18 1999-12-17 Immunological compositions and vaccines containing N-formyl methionyl peptide as adjuvant

Publications (1)

Publication Number Publication Date
CY1111372T1 true CY1111372T1 (el) 2015-08-05

Family

ID=22808169

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071100731T CY1106635T1 (el) 1998-12-18 2007-06-04 Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια
CY20111100355T CY1111372T1 (el) 1998-12-18 2011-04-05 Ανοσολογικη συνθεση και εμβολια που περιεχουν ν-φορμυλομεθειονυλο πεπτιδιο ως ανοσοενισχυτικο

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071100731T CY1106635T1 (el) 1998-12-18 2007-06-04 Ανοσοενισχυτικο που περιεχει ν - φορμυλο μεθειονυλο-πεπτιδια για εμβολια

Country Status (14)

Country Link
US (1) US6017537A (el)
EP (2) EP1800692B1 (el)
JP (1) JP2002532436A (el)
AT (2) ATE496630T1 (el)
AU (1) AU773697B2 (el)
CA (2) CA2718376A1 (el)
CY (2) CY1106635T1 (el)
DE (2) DE69935866T2 (el)
DK (2) DK1800692T3 (el)
ES (2) ES2358540T3 (el)
NZ (1) NZ510544A (el)
PT (2) PT1800692E (el)
SI (2) SI1800692T1 (el)
WO (1) WO2000035482A2 (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010018579A1 (en) 1998-12-18 2001-08-30 Walter Klemp Disposable absorbent garment having stretchable side waist regions
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
IL152922A0 (en) * 2000-05-23 2003-06-24 Histatek Llc Complexes of alpha-6 integrin subunits with small peptides and methods for treating indications resulting from modulation of integrin-mediated responses by altering signal transduction
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) * 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
MXPA05003049A (es) 2002-09-19 2005-11-17 Us Gov Health & Human Serv Polipeptidos de phlebotomus ariasi, polipeptidos de phlebotomus perniciosus y metodos de uso.
MXPA05004714A (es) 2002-10-29 2006-03-17 Us Gov Health & Human Serv Polipeptidos de lutzomyia longipalpis y metodos de uso.
EP1581558A2 (en) * 2003-01-07 2005-10-05 Neuromed Technologies, Inc. Fluorescence based t-type channel assay
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
CA2604243C (en) 2004-04-14 2015-11-24 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
US7806880B2 (en) * 2005-03-18 2010-10-05 The Procter & Gamble Company Pull-on wearable article with informational image
US7887522B2 (en) 2005-03-18 2011-02-15 The Procter And Gamble Company Pull-on wearable article with informational image
US20060264858A1 (en) * 2005-05-20 2006-11-23 Roe Donald C Multi-functional training garment
JP2009512421A (ja) 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
US7432413B2 (en) 2005-12-16 2008-10-07 The Procter And Gamble Company Disposable absorbent article having side panels with structurally, functionally and visually different regions
US8664467B2 (en) 2006-03-31 2014-03-04 The Procter & Gamble Company Absorbent articles with feedback signal upon urination
EP3669894A3 (en) * 2006-06-30 2020-08-26 Syntab Therapeutics GmbH Novel multifunctional compounds for pharmaceutical purposes
CA2851763A1 (en) 2006-12-04 2008-06-12 The Procter & Gamble Company Absorbent articles comprising graphics
MX348137B (es) 2008-05-08 2017-05-29 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
US9400873B2 (en) 2011-12-21 2016-07-26 Deka Products Limited Partnership System, method, and apparatus for dispensing oral medications
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SMT201900129T1 (it) 2011-07-20 2019-05-10 Centre Nat Rech Scient Vaccino ricombinante contro il virus della leucemia felina contenente un gene ottimizzato dell'involucro del virus della leucemia felina
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US10563681B2 (en) 2011-12-21 2020-02-18 Deka Products Limited Partnership System, method, and apparatus for clamping
US12205697B2 (en) 2011-12-21 2025-01-21 Deka Products Limited Partnership Pill dispenser
NZ700470A (en) 2012-03-20 2016-04-29 Merial Inc Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
WO2013170433A1 (en) 2012-05-15 2013-11-21 The Procter & Gamble Company Absorbent article having characteristic waist end
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2015175672A1 (en) 2014-05-14 2015-11-19 Merial, Inc. Methods for freeze-drying and rehydrating biologics
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
KR102726776B1 (ko) * 2021-07-09 2024-11-06 포항공과대학교 산학협력단 포밀 메티오닌 특이 항체 제조를 위한 신규한 항원 펩타이드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor

Also Published As

Publication number Publication date
JP2002532436A (ja) 2002-10-02
AU2845100A (en) 2000-07-03
US6017537A (en) 2000-01-25
ES2284285T3 (es) 2007-11-01
DE69935866T2 (de) 2008-01-10
CA2342609A1 (en) 2000-06-22
CA2718376A1 (en) 2000-06-22
DK1800692T3 (da) 2011-03-28
DE69943170D1 (de) 2011-03-10
WO2000035482A3 (en) 2000-10-26
NZ510544A (en) 2003-04-29
CA2342609C (en) 2010-11-16
ES2358540T3 (es) 2011-05-11
EP1800692A1 (en) 2007-06-27
CY1106635T1 (el) 2012-01-25
AU773697B2 (en) 2004-06-03
ATE359817T1 (de) 2007-05-15
EP1800692B1 (en) 2011-01-26
PT1800692E (pt) 2011-03-31
PT1140166E (pt) 2007-06-27
DK1140166T3 (da) 2007-07-02
DE69935866D1 (de) 2007-05-31
SI1800692T1 (sl) 2011-05-31
ATE496630T1 (de) 2011-02-15
HK1110769A1 (en) 2008-07-25
SI1140166T1 (sl) 2007-08-31
EP1140166A2 (en) 2001-10-10
WO2000035482A2 (en) 2000-06-22
EP1140166B1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
CY1111372T1 (el) Ανοσολογικη συνθεση και εμβολια που περιεχουν ν-φορμυλομεθειονυλο πεπτιδιο ως ανοσοενισχυτικο
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
DK1198250T3 (da) FC-fusionsproteiner til forstærkning af protein- og peptidantigeners immunogenicitet
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
MX9207113A (es) Fragmento de adn, peptido que comprende una proteina superficial ha de un virus de gripe a y vacuna que comprende tal peptido.
DE60141969D1 (de) Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell-immunantwort gegen antigen
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
YU46753B (sh) Rekombinantni virus
DE69839405D1 (de) Verfahren und Reagenzien zur Erzeugung einer CD8+ T-Zellen Immunantwort
DE60238471D1 (de) Proteosom-liposaccharid-vakzine-adjuvans
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
DK1033995T3 (da) Hele eller sprængte insektceller som adjuvans for antigener
HUP9902438A2 (hu) Parapoxvírus vektorok
DK1542732T3 (da) Fusionsproteiner af Mycobacterium tuberculosis
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
KR860004146A (ko) 경구용 백신의 제조방법
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
WO2000000216A3 (en) Use of poxviruses as enhancer of specific immunity
ATE355853T1 (de) Heterologer schutz, induziert durch immunisierung mit der invaplex-vakzine
ATE141328T1 (de) Rekombinante vakzine gegen coccidiose
DK0431327T3 (da) Syntetisk vaccine til specifik induktion af cytotoksiske T-lymfocytter
DE60036692D1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung